Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX) presented results from the Phase 2 STS-J01 clinical trial evaluating Pedmark (sodium thiosulfate ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE